


In the Claims:

✓
Please cancel claims 1, 2, 3, and 5; Amend Claims 4, 6, 9, 13 and 15; and add new claims 16-21.

Please amend the claims as follows:

1. (Cancelled) ~~A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament and (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid.~~


2. (Cancelled) ~~A pharmaceutical formulation according to claim 1 wherein the ester of fluticasone is a compound of formula (I)~~



~~wherein R represents ethyl or a 5 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, optionally substituted by one or more methyl or halogen atoms or a solvate thereof.~~

3. (Cancelled) ~~A pharmaceutical formulation according to claim 2 wherein R represents ethyl (i.e. the fluticasone ester is fluticasone propionate).~~

4. (Currently amended) A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament, wherein the ester of fluticasone is a compound of formula (I)



~~A pharmaceutical formulation according to claim 2 wherein R represents furan-2-yl~~
and (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid

5. (Cancelled) ~~A pharmaceutical formulation according to claim 1 wherein the solubilising agent is a surfactant.~~

6. (Currently amended) A pharmaceutical formulation ~~according to claim 5~~
comprising an aqueous carrier liquid having dissolved therein (a) an ester of
fluticasone or a solvate thereof as medicament and (b) a solubilising agent for
assisting the solubilisation of the medicament in the aqueous carrier liquid, wherein
the solubilising agent is a surfactant ~~wherein the surfactant is selected from the group~~
consisting of a α -[4-(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxypoly(oxy-1,2-ethanediyl) polymer (also known as a octylphenoxy polyethoxyethanol) and a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.

7. (Original) A pharmaceutical formulation according to claim 4 wherein the solubilising agent is a surfactant selected from the group consisting of a α -[4-(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxypoly(oxy-1,2-ethanediyl) polymer (also known as a octylphenoxy polyethoxyethanol) and a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.

8. (Original) A pharmaceutical formulation according to claim 6 wherein the surfactant is a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.

9. (Currently Amended) A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid, and (c) ~~A pharmaceutical formulation according to claim 1 which further has dissolved therein~~ a hydroxy containing organic co-solvating agent or phosphatidyl choline.

10. (Original) A pharmaceutical formulation according to claim 7 which further has dissolved therein a hydroxy containing organic co-solvating agent or phosphatidyl choline.

11. (Currently Amended) A pharmaceutical formulation according to claim 9 wherein the ~~the~~ hydroxy containing organic co-solvating agent is dextrose.

12. (Currently Amended) A pharmaceutical formulation according to claim 10 wherein the ~~the~~ hydroxy containing organic co-solvating agent is dextrose.

13. (Currently Amended) A container containing a pharmaceutical formulation according to claim ~~1~~ 4 fitted with a metering valve.

14. (Original) A device adapted for intranasal delivery of a pharmaceutical formulation comprising a container according to claim 13.

15. (Currently Amended) A method of treatment of inflammatory and/or allergic conditions of the nasal passages which comprises administering to the nose a pharmaceutical formulation according to claim ~~1~~ 4.

Add the following claims:

16. (Newly added) A container containing a pharmaceutical formulation according to claim 6 fitted with a metering valve.

17. (Newly added) A device adapted for intranasal delivery of a pharmaceutical formulation comprising a container according to claim 16.

18. (Newly added) A method of treatment of inflammatory and/or allergic conditions of the nasal passages which comprises administering to the nose a pharmaceutical formulation according to claim 6.

19. (Newly added) A container containing a pharmaceutical formulation according to claim 9 fitted with a metering valve.

20. (Newly added) A device adapted for intranasal delivery of a pharmaceutical formulation comprising a container according to claim 19.

21. (Newly added) A method of treatment of inflammatory and/or allergic conditions of the nasal passages which comprises administering to the nose a pharmaceutical formulation according to claim 9.

REMARKS / ARGUMENTS

The following Amendment A is made in response to the Official Action dated 24 January, 2003. In this Amendment, claims 1, 2, 3, and 5 have been cancelled; Claims 4, 6, 9, 13, and 15 have been amended, and new claims 16-21 have been added. Thus, Claims 4, 6-21 are currently pending.

The present invention relates to aqueous solutions of fluticasone esters and their solvates, formulated with a solvating agent:

Claim 4 claims a particular furan-2-yl molecule of the compound of formula (I). Claims 7, 10, 12-15 depend directly or indirectly from claim 4, and are treated together below.

Claim 6 relates to a genus of fluticasone esters formulated with particular surfactant types. Claims 8, 16-18 depend directly or indirectly from claim 6 and each is treated together below.

Lastly, Claim 9 includes a particularly useful class of co-solvating agents. Claims 11, 19-21 depend, directly or indirectly, from claim 9, and as such are discussed together with claim 9 below.